Bristol-Myers Squibb (BMS) and Syngene International have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
Since 2007, BMS has been working with Syngene and its corporate parent, Biocon, to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Centre (BBRC) in Bangalore.
The US-India collaboration has produced six drug candidates for further study and also helped BMS reduce the time and costs associated with advancing new compounds to first-in-human studies. One drug candidate currently in clinical trials was discovered at BBRC and early nonclinical development work done at BBRC has enabled most of Bristol-Myers Squibb’s small molecule assets to advance to later stages of development over the last five years.
Peter Bains, Director, Syngene International said, “We are delighted to extend our discovery and development partnership with Bristol-Myers Squibb for another five years. The scope of Syngene’s engagement has expanded to encompass a broad range of integrated service offerings across the drug discovery and development continuum. We remain committed to supporting BMS in their pursuit of developing new and innovative medicines for the future.”
Francis Cuss, Executive Vice President and Chief Scientific Officer, BMS said, “The BBRC has supported the non-clinical development of a large proportion of our small-molecule portfolio assets since its inception, and is a premier example of the high-quality innovative drug hunting that is taking place in India today.”
EP News Bureau – Mumbai
- Advertisement -
